title: Effect of edaravone on plasma monocyte chemoattractant protein-1 levels in patients with acute myocardial infarction.
abstract: BACKGROUND
  Monocyte chemoattractant protein-1 (MCP-1) plays an important role in the pathogenesis of acute coronary syndrome. We have recently demonstrated that the administration of edaravone before reperfusion attenuated reperfusion injury in patients with acute myocardial infarction (AMI).
  
  
  METHODS
  Plasma MCP-1 levels were measured in 45 consecutive patients with AMI (edaravone group, n=25; control group, n=20). In the edaravone group, 30 mg edaravone was intravenously infused just before reperfusion. Plasma samples were obtained before and at 24h, 3, 5, 7, and 14 days after reperfusion. Cardiovascular events were defined as cardiac death, subacute thrombosis, or fatal arrhythmia. Heart failure requiring rehospitalization was evaluated at 12 months after reperfusion.
  
  
  RESULTS
  Plasma MCP-1 levels were not different between the two groups before reperfusion. Compared with the placebo group, the edaravone group had statistically lower maximum creatine kinase-MB levels (218±31 IU/l versus 145±21 IU/l, p<0.05) and plasma MCP-1 levels on day 3 after reperfusion (873±118 pg/ml versus 516±66 pg/ml, p<0.05). Heart failure requiring rehospitalization occurred in four patients in the control group, but did not occur in the edaravone group (p<0.05). At 12 months after reperfusion, left ventricular ejection fraction was statistically higher in the edaravone group than in the control group (62±2% versus 54±3%, p<0.05).
  
  
  CONCLUSIONS
  Edaravone suppressed plasma MCP-1, improved left ventricular ejection fraction, and reduced rehospitalization due to heart failure. Suppression of plasma MCP-1 level by edaravone might induce better prognosis for AMI patients.
authors: Fukuoka Tokushukai Medical Center, 4-5 Sukukita, Kasuga, Fukuoka 816-0864, Japan. nakamurayoshi2004@yahoo.co.jp
authors: Yoshinori
authors: Y
authors: Nakamura
authors: Yoshihiro
authors: Y
authors: Yamada
authors: Hideki
authors: H
authors: Shimomura
authors: Yasuhiro
authors: Y
authors: Nagayoshi
authors: Kenichi
authors: K
authors: Tsujita
authors: Takuro
authors: T
authors: Yamashita
authors: Masaya
authors: M
authors: Fukuda
authors: Keisuke
authors: K
authors: Ohba
authors: Hisato
authors: H
authors: Nako
authors: Yuji
authors: Y
authors: Ogura
authors: Tadasuke
authors: T
authors: Chitose
authors: Munetaka
authors: M
authors: Yamaguchi
authors: Takeshi
authors: T
authors: Nagata
authors: Hirofumi
authors: H
authors: Soejima
authors: Koichi
authors: K
authors: Kaikita
authors: Seigo
authors: S
authors: Sugiyama
authors: Hisao
authors: H
authors: Ogawa
mesh_terms: D000368:Aged; D015906:Angioplasty, Balloon, Coronary; D000983:Antipyrine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D015415:Biomarkers / Q000097:blood; D018932:Chemokine CCL2 / Q000097:blood* / Q000502:physiology; D000077553:Edaravone; D005260:Female; D016166:Free Radical Scavengers / Q000008:administration & dosage*; D006333:Heart Failure / Q000517:prevention & control; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000209:etiology / Q000503:physiopathology / Q000628:therapy*; D015428:Myocardial Reperfusion Injury / Q000517:prevention & control*; D010359:Patient Readmission / Q000706:statistics & numerical data; D011379:Prognosis; D013318:Stroke Volume; D016277:Ventricular Function, Left
chemical_list: D015415:Biomarkers; C111835:CCL2 protein, human; D018932:Chemokine CCL2; D016166:Free Radical Scavengers; D000077553:Edaravone; D000983:Antipyrine